TABLE 2.
Description of isolates utilized in this study and summary of PCR analyses
| Species and isolate(s) | Origina | In vitro passageb | PCR results with uhb(+)-E470(−) primer setc |
|---|---|---|---|
| B. burgdorferi | |||
| 297, 297CH | Human CSF, CT | U (I), 7 (I) | + (mp), + |
| N40,d N40CH, B31, B31Td | Ixodes scapularis, NY | L (I), 7 (I), L (I), L (I) | +, +, +, + |
| R100, T2, 25015 | I. scapularis, NY | 4 (I), 8, 6 (I) | + (p), + (mp), + |
| CA2, CA3, CA12 | Ixodes pacificus, CA | 11, 11, 25 | +, +, + |
| CA4, CA7, CA8, CA9 | I. pacificus, CA | 5, 7, 8, 3 | +, +, +, + |
| CA13 | Ixodes neotomae, CA | 9 | + |
| LP3, LP4, LP5, LP7 | Human, CT | 3, 3, 3, 3 | +, +, +, + |
| 272 | Human EM, USA | 28 | + (mp) |
| NY186 | Human EM, NY | 20 | + |
| HBNCd | Human blood, CA | 2 | + |
| JD1d | I. scapularis, MA | 4 (I) | + (p) |
| VS134, VS307 | Ixodes ricinus, Switzerland | 8, 7 | +/−, + |
| B. garinii | |||
| IP90, IP89 | Ixodes persulcatus, Russia | H, 4 | + (p), + |
| VS102, VSBP | I. ricinus, Switzerland | 9, 8 | +, − |
| G2 | Human CSF, Germany | H | − |
| 153 | I. ricinus, France | 11 | +/− |
| FRG, Pbi, N34 | I. ricinus, Germany | 11, U, H | −, −, +/− |
| G25 | I. ricinus, Sweden | H | +/− |
| B5-92, B4-91 | Human EM, Norway | L, L | +, + |
| B4-87, B6-91 | I. ricinus, Norway | L, L | +/−, + |
| B. valaisiana sp. nov. VS116 | I. ricinus, Switzerland | 9 | + |
| B. afzelii | |||
| J1 | I. persulcatus, Japan | U | + |
| Pbo | Human CSF, Germany | 3 | + |
| IP21, IP3 | I. persulcatus, Russia | H, H | + (p), + |
| Bo23, PGaud | Human EM, Germany | U, L | +, + (mp) |
| Pkod | Human EM, Switzerland | U | + |
| UMO1, ECM1, VS461 | Human skin, Sweden | U, U, 9 | + (p), +, +/− |
| B. andersonii | |||
| 21038d | Ixodes dentatus, NY | L | + (p) |
| 19857 | Rabbit kidney, NY | 22 | +/− |
| B. japonica IKA2, HO14 | Ixodes ovatus, Japan | U, U | + (mp), − |
a
CSF, cerebrospinal fluid; EM, erythema migrans; CT, Connecticut; NY, New York; CA, California; USA, United States; MA, Massachusetts.
b
U, unknown passage history; L, passaged in vitro fewer than 15 times; H, passaged more than 30 times; I, confirmed to be infectious.
c
m, multiple bands were obtained; p, amplicons of a size different (polymorphic) from that predicted were obtained; +, strong amplification; +/−, weak amplification; −, no amplification.
d
The isolate was cloned by plating.